Code | CSB-RA923075A0HU |
Size | US$210 |
Order now | |
Image | |
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
WB | 1:500-1:5000 |
B cells were isolated from the animal who received immunization with a synthetic peptide derived from human F9 and then fused with myeloma cells to generate hybridomas. The variable light and heavy domains of the hybridomas were sequenced to construct a vector for a recombinant generation. The F9 monoclonal antibody gene-containing vector was transfected into cells for cultivation, and the F9 recombinant monoclonal antibody was isolated and purified using affinity chromatography from the cell culture supernatant. The purified antibody was specifically tested for human F9 protein detection in ELISA and WB applications.
Coagulation factor IX (F9) is a protein that plays an important role in blood clotting. It is synthesized in the liver and circulates in the bloodstream in an inactive form. When a blood vessel is damaged, a series of reactions is initiated that leads to the activation of factor IX to its active form, factor IXa. Activated factor IX, together with activated factor VIII and calcium ions, forms a complex that activates factor X to factor Xa, which in turn leads to the conversion of prothrombin to thrombin. Thrombin then converts fibrinogen to fibrin, which forms the basis of a blood clot. Mutations in the gene encoding factor IX can lead to hemophilia B, a bleeding disorder characterized by a deficiency in this clotting factor.
There are currently no reviews for this product.